<div id="readability-page-1"><p>Immuron (IMRN) stock fell hard on Wednesday after the biopharmaceutical company announced results from the Uniformed Services University's P2TD study of enterotoxigenic E. coli (ETEC) hyperimmune bovine colostrum (IMM-124E) manufactured by a third party and taken with Travelan. This treatment was tested for effectiveness in maintaining gut health during deployment and travel.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Immuron noted that this clinical trial failed to meet its primary endpoint of statistical significance. The company noted that since the trial didn't follow its directions for use of Travelan, it doesn't consider the data to be a reflection of Travelan's performance. However, it will use the data for its dosing recommendations during its upcoming End-of-Phase 2 meeting with the FDA.</p> <p>Immuron also highlighted ongoing contracts with government departments, including the Naval Medical Research Command, the Walter Reed Army Institute of Research, and the Department of Enteric Diseases at the Armed Forces Research Institute of Medical Sciences (AFRIMS). These ongoing contracts relate to the development of Travelan and the creation of novel vaccines targeting Campylobacter and Shigella.</p> <h2><strong>Immuron Stock Movement Today</strong></h2> <p>Immuron stock was down 25.17% in pre-market trading on Wednesday, following a 2.72% rise yesterday. The stock has decreased 11.18% year-to-date and 32.59% over the past 12 months.</p> <p>With today's news came heavy trading of IMRN stock, as some 200,000 shares changed hands, compared to a three-month daily average of about 76,000 units.</p></div>

IMRN

<p>Immuron's stock fell 25.17% in pre-market trading after announcing that a clinical trial of its ETEC treatment failed to meet its primary endpoint. The company plans to use the data for dosing recommendations in an upcoming FDA meeting. Despite the setback, Immuron continues to work on contracts with government departments for Travelan and vaccine development.</p>

Why Is Immuron Stock (IMRN) Down Today?